While Maine’s adult-use cannabis products are already tested for contaminants and potency, medical marijuana remains unregulated in this regard—making Maine the only state without testing requirements for its medical cannabis program. A 2023 review by the state’s Office of Cannabis Policy found that nearly half of tested medical cannabis products would fail to meet adult-use standards.
The initial proposal, Legislative Document 104, sought to implement seed-to-sale tracking and mandatory testing for contaminants such as mold, heavy metals, and pesticides across all cannabis sectors. However, strong public opposition and concerns from industry stakeholders led to its postponement.
In its place, lawmakers are preparing to introduce a revised version—LD 1847—in the next session. The bill, sponsored by Democratic Representative Anne Graham, retains the testing and tracking mandates while introducing potency caps for edible cannabis products. Graham noted that the goal is to protect patients and ensure product safety while helping the medical cannabis sector remain viable.
During hearings earlier this year, the legislature received over 1,000 written testimonies, many expressing concern that stricter regulations could undermine the state’s long-standing medical marijuana program. Jennifer Belcher, president of the Maine Cannabis Union, warned that the proposed changes could drive providers out of business and limit patient access.
As lawmakers prepare for renewed debate in 2026, the conversation will likely focus on how to modernize Maine’s cannabis policy without crippling its medical marijuana infrastructure. The future of safe, regulated access hangs in the balance.
Dabbin-Dad Newsroom
If you liked this post, say thanks by sharing it
